发明名称 |
MODULATION OF IL-2- AND IL-15-MEDIATED T CELL RESPONSES |
摘要 |
The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo, reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity). |
申请公布号 |
WO0222805(A3) |
申请公布日期 |
2003.07.17 |
申请号 |
WO2001US28612 |
申请日期 |
2001.09.14 |
申请人 |
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.;LI, XIAN, CHANG;STROM, TERRY;ZHENG, XIN, XIAO |
发明人 |
LI, XIAN, CHANG;STROM, TERRY;ZHENG, XIN, XIAO |
分类号 |
C12N15/09;A61K31/436;A61K38/00;A61K38/20;A61K39/395;A61K45/00;A61P1/00;A61P3/10;A61P5/14;A61P17/00;A61P17/06;A61P19/02;A61P19/04;A61P19/08;A61P21/00;A61P21/04;A61P25/00;A61P29/00;A61P31/18;A61P35/00;A61P37/02;A61P37/06;A61P43/00;C07K14/54;C07K14/55;C12N5/06;C12Q1/02 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|